NASDAQ:ABUS - Arbutus Biopharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$9.95 +0.60 (+6.42 %)
(As of 09/20/2018 04:00 PM ET)
Previous Close$9.35
Today's Range$9.32 - $10.15
52-Week Range$4.30 - $12.60
Volume281,279 shs
Average Volume302,158 shs
Market Capitalization$529.11 million
P/E Ratio-5.25
Dividend YieldN/A
Arbutus Biopharma logoArbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The company's lead candidate is ARB-1467, which is in a Phase II trial to block production of HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also include AB-423, a core protein inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection; and AB-452, an HBV RNA Destabilizer, which is in preclinical study. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates comprising N-Acetylgalactosamine conjugate technology, cccDNA targeting agents, and checkpoint inhibition. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) that has been completed Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and RNA-based neoantigen immunotherapy products. The company has strategic alliance, licensing, and research collaboration agreements with Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Marina Biotech Inc.; U.S. National Institutes of Health; and The Baruch S. Blumberg Institute and Drexel University. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.01
Current Ratio13.67
Quick Ratio13.67


Trailing P/E Ratio-5.25
Forward P/E Ratio-6.14
P/E GrowthN/A

Sales & Book Value

Annual Sales$10.70 million
Price / Sales51.52
Cash FlowN/A
Price / CashN/A
Book Value$2.41 per share
Price / Book4.13


EPS (Most Recent Fiscal Year)($1.79)
Net Income$-84,410,000.00
Net Margins-515.00%
Return on Equity-75.07%
Return on Assets-38.94%


Outstanding Shares55,400,000
Market Cap$529.11 million

Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Corp (NASDAQ:ABUS) announced its earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.09. The biopharmaceutical company earned $1.20 million during the quarter. Arbutus Biopharma had a negative return on equity of 75.07% and a negative net margin of 515.00%. View Arbutus Biopharma's Earnings History.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Arbutus Biopharma.

What price target have analysts set for ABUS?

5 brokerages have issued twelve-month price targets for Arbutus Biopharma's stock. Their predictions range from $5.00 to $13.00. On average, they expect Arbutus Biopharma's stock price to reach $9.50 in the next twelve months. This suggests that the stock has a possible downside of 4.5%. View Analyst Price Targets for Arbutus Biopharma.

What is the consensus analysts' recommendation for Arbutus Biopharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arbutus Biopharma.

What are Wall Street analysts saying about Arbutus Biopharma stock?

Here are some recent quotes from research analysts about Arbutus Biopharma stock:
  • 1. According to Zacks Investment Research, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. " (8/8/2018)
  • 2. Chardan Capital analysts commented, "We maintain our BUY rating and are increasing our 12-month price target to $11.00: We continue to believe that Arbutus has the potential to become a significant competitor in the chronic hepatitis B virus (HBV) infection treatment market. We believe that future progress updates from its pipeline programs could serve as potential value creation events for the stock over the next 12-18 months. First up will be interim data in 2 study of the Company’s lead RNAi asset, ARB-1467, used as combination therapy for HBV. The Company’s second generation capsid assembly inhibitor, ARB-506, is now being evaluated in a Phase 1 study, which dosed its first patient yesterday, in an initial cohort of healthy human volunteers, and could report topline data by mid-2019." (7/16/2018)

Are investors shorting Arbutus Biopharma?

Arbutus Biopharma saw a decrease in short interest in August. As of August 31st, there was short interest totalling 1,682,416 shares, a decrease of 31.2% from the August 15th total of 2,445,318 shares. Based on an average daily trading volume, of 181,110 shares, the days-to-cover ratio is currently 9.3 days. Currently, 5.0% of the shares of the stock are sold short. View Arbutus Biopharma's Current Options Chain.

Who are some of Arbutus Biopharma's key competitors?

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the folowing people:
  • Dr. Mark Joseph Murray, Pres, CEO & Director (Age 69)
  • Dr. Michael J. Sofia, Chief Scientific Officer (Age 60)
  • Dr. Elizabeth Howard, Exec. VP & Gen. Counsel (Age 64)
  • Mr. Bruce G. Cousins, Consultant (Age 57)
  • Mr. David C. Hastings, Chief Financial Officer (Age 57)

Has Arbutus Biopharma been receiving favorable news coverage?

News stories about ABUS stock have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arbutus Biopharma earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Arbutus Biopharma.

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by many different of institutional and retail investors. Top institutional investors include RTW Investments LP (9.32%), BlackRock Inc. (4.32%), Bank of Montreal Can (1.71%), Northern Trust Corp (0.54%), Renaissance Technologies LLC (0.45%) and Victory Capital Management Inc. (0.29%). View Institutional Ownership Trends for Arbutus Biopharma.

Which major investors are selling Arbutus Biopharma stock?

ABUS stock was sold by a variety of institutional investors in the last quarter, including K2 Principal Fund L.P. and Victory Capital Management Inc.. View Insider Buying and Selling for Arbutus Biopharma.

Which major investors are buying Arbutus Biopharma stock?

ABUS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of Montreal Can, Northern Trust Corp, Bank of New York Mellon Corp, Bank of New York Mellon Corp, Millennium Management LLC, PNC Financial Services Group Inc. and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Arbutus Biopharma.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $9.95.

How big of a company is Arbutus Biopharma?

Arbutus Biopharma has a market capitalization of $529.11 million and generates $10.70 million in revenue each year. The biopharmaceutical company earns $-84,410,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. Arbutus Biopharma employs 130 workers across the globe.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]

MarketBeat Community Rating for Arbutus Biopharma (NASDAQ ABUS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  308 (Vote Outperform)
Underperform Votes:  216 (Vote Underperform)
Total Votes:  524
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote "Outperform" if you believe ABUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel